Flu A/Flu B/2019-nCoV Ag 3 in 1 Combo Test

Key features and details:

Flu A/Flu B/2019-nCoV Ag 3 in 1 Combo Test is a rapid immunoassay designed for the qualitative detection and differentiation of nucleocapsid antigen from Influenza Virus type A, Influenza Virus type B, and 2019-nCoV directly from nasopharyngeal swab specimens. It aids in diagnosing infections caused by these viruses.

Packaging Size:

25 Tests

SKU:

03ABCA0025

Product Description:

Flu A/Flu B/2019-nCoV Ag 3 in 1 Combo Test is a lateral flow chromatographic immunoassay designed for the qualitative detection and differentiation of nucleocapsid antigen from Influenza Virus type A, Influenza Virus type B, and 2019-nCoV in human nasopharyngeal swab specimens. The test uses monoclonal antibodies specific to each virus's nucleocapsid protein. The specimen is applied to the test device, where antigens, if present, form immune complexes with the monoclonal antibodies. These complexes migrate to the test zone and are captured by another set of monoclonal antibodies, forming a visible colored line. The control line (C) ensures the test is performed correctly.

Specifications:

Disease Screened:

Influenza A, Influenza B, COVID-19

SKU:

03ABCA0025

Analyte / Target:

Influenza A Virus, Influenza B Virus, 2019-nCoV

Packaging Size

25 Tests

Sample Type:

Nasopharyngeal Swab

Diagnostic Platforms:

Rapid Test

Diagnostic Solutions:

Infectious Disease

Species Reactivity:

Human

This kit is for in vitro diagnosis use only. The test results are for clinical reference only and should not be used as the sole criteria for the diagnosis of Flu A/Flu B/2019-nCoV infection. As with all diagnostic tests, all results must be interpreted together with other clinical information available to the physician.
The test device cannot be reused.
Do not use kits or reagents after the expiration dates shown on the labels.
Read results within 15~30 minutes.
This test should be performed at 15℃ to 30℃. If stored refrigerated, ensure that the pouch and diluent are brought to operating temperature before performing testing.
Humidity and temperature can adversely affect results. Testing must be performed within one hour after unsealing the pouch.
Testing the specimen immediately after collection is preferred, and it should not be repeatedly frozen and thawed.
Collect specimens using the swabs and diluent provided by this reagent. Do not mix different batches of the test device and diluent.
Inadequate or inappropriate specimen collection, storage, and transportation will likely result in false test results. Due to the importance of specimen quality, training in specimen collection is highly recommended.
If a sample initially tests positive for Flu A/2019-nCoV, further confirmation is required. If necessary, consult your local public health prevention agency.
For testing Influenza A viruses or subtypes, small changes in epitopes due to small mutations in the nucleic acid sequence may result in negative results.
Operators should wear protective clothing, masks, and gloves and take other appropriate safety precautions to avoid or reduce the risk of infection.
Decontaminate and dispose of all potentially infectious materials in accordance with local, state, and federal regulations.

The kit is for qualitative detection and auxiliary diagnosis use only.
This kit is limited to testing human nasopharyngeal swabs.
If the operator lacks experience in specimen collection and handling, special training or guidance procedures are recommended. Protective clothing, such as a laboratory coat, disposable gloves, and goggles, should be worn when collecting specimens.
Proper specimen collection, storage, and shipment are critical to this test's performance. Incorrect specimen collection, transportation, and processing, as well as low virus titer in specimens, may lead to false negative results.
Due to the methodology's limitations, it is suggested that the nucleic acid detection method be used to recheck and confirm the negative test results.
Genetic variations in the virus may lead to changes in the epitope, which can lead to false negative results. This may happen with reagents using monoclonal antibodies.
For an emergent Influenza A virus, the best type of sample to be tested and the best sampling time after infection (virus titer peak) may not be confirmed, so sampling multiple times in the same patient at multiple sites can reduce the likelihood of false negative results.
Samples were taken with certain medications, such as high concentrations of over-the-counter and prescription drugs (nasal sprays), which can interfere with results. If the results are suspicious, repeat the test.
Due to limitations in antigen detection reagent methodology, its analytical sensitivity is generally lower than that of nucleic acid reagents. Therefore, laboratory personnel should pay more attention to the negative results and make a comprehensive judgment based on other testing results.
Further experimentation with positive results is recommended to confirm the subtype of Influenza A virus and consult the local public health prevention agency for consultation and treatment.

Sohrabi C, Alsafi Z, O'Neill N, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020, 76:71-76.
Chang, C.-k., Hou, M.-H., Chang, C.-F., Hsiao, C.-D., & Huang, T.-h. J. A. r. (2014). The SARS coronavirus nucleocapsid protein forms and functions. 103, 39-50.
The Impetus of COVID-19 in Multiple Organ Affliction apart from Respiratory Infection: Pathogenesis, Diagnostic Measures and Current Treatment Strategy. Baby, Devan, Nair et al. Infect Disord Drug Targets (2020).
Bouvier, N.M. and Palese, P. (2008). The Biology of Influenza Viruses. Vaccine.26 (Suppl 4): D49–D53.
Centers for Disease Control and Prevention: Influenza type A viruses.
World Health Organization: Influenza (seasonal).

For more information on purchasing and further inquiries

Purchase Information:

CONTACT US: 800-678-6081 order@beb.bio